{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=5",
    "query": {
      "condition": "Endocrine Disorders of Female Reproductive System",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 2050,
    "total_pages": 205,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders+of+Female+Reproductive+System&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T09:29:40.624Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06910657",
      "title": "IDOV-Immune for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Bladder Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Cervical Cancers",
        "Head and Neck Cancers",
        "Adrenal Gland Tumors"
      ],
      "interventions": [
        {
          "name": "IDOV-Immune (oncolytic vaccinia virus)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ViroMissile, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-08-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910657"
    },
    {
      "nct_id": "NCT02657928",
      "title": "Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Positive",
        "Postmenopausal",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2016-07-08",
      "completion_date": "2020-10-07",
      "has_results": true,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02657928"
    },
    {
      "nct_id": "NCT00407563",
      "title": "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Abraxane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Accelerated Community Oncology Research Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2007-01",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2012-04-05",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • La Verne, California • Athens, Georgia + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407563"
    },
    {
      "nct_id": "NCT06161493",
      "title": "ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Recurrent Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ZEN003694",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Haider Mahdi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-01-23",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161493"
    },
    {
      "nct_id": "NCT07932106",
      "title": "Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "High Grade Serous Ovarian",
        "Ovarian Adenocarcinoma",
        "Ovarian Cancer",
        "Serous Adenocarcinoma of Ovary",
        "Ovarian Cancer (OvCa)"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2026-12-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07932106"
    },
    {
      "nct_id": "NCT00349258",
      "title": "The Use of GnRH Agonist Trigger in the Prevention of OHSS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Connecticut",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 39 Years · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2004-08",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2006-07-06",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349258"
    },
    {
      "nct_id": "NCT07224464",
      "title": "The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Stage 4 Cancer"
      ],
      "interventions": [
        {
          "name": "The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "New Phase Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-12-16",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224464"
    },
    {
      "nct_id": "NCT05697198",
      "title": "PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer",
        "Ovarian Cancer",
        "Uterine Cancer",
        "Colorectal Cancer",
        "Stomach Cancer",
        "Esophageal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Breast Cancer",
        "Head and Neck Cancer",
        "Soft Tissue Sarcoma",
        "Rhabdomyosarcoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "OmniSeq Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Labcorp Corporation of America Holdings, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1429,
      "start_date": "2021-04-19",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 8,
      "location_summary": "Fort Payne, Alabama • Orange City, Florida • Stuart, Florida + 5 more",
      "locations": [
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Dublin",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05697198"
    },
    {
      "nct_id": "NCT05001347",
      "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Gastrointestinal Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "TJ004309",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "I-Mab Biopharma US Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-02",
      "completion_date": "2023-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001347"
    },
    {
      "nct_id": "NCT01962948",
      "title": "Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "ganetespib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2013-10-09",
      "completion_date": "2018-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-11-22T09:29:40.624Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962948"
    }
  ]
}